Associated Papers
Altered CYP19A1 and CYP3A4 Activities Due to Mutations A115V, T142A, Q153R and P284L in the Human P450 Oxidoreductase.
Udhane SS et al.
Frontiers in Pharmacology, 2017
Pharmacogenomics of human P450 oxidoreductase.
Pandey AV et al.
Frontiers in Pharmacology, 2014
Genotype-phenotype analysis in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency.
Krone N et al.
The Journal of Clinical Endocrinology and Metabolism, 2012
Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism.
Flück CE et al.
Biochemical and Biophysical Research Communications, 2010
Restoration of mutant cytochrome P450 reductase activity by external flavin.
Nicolo C et al.
Molecular and Cellular Endocrinology, 2010
Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.
Flück CE et al.
Fundamental & Clinical Pharmacology, 2007
Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis.
Huang N et al.
American Journal of Human Genetics, 2005
Select a paper to view details